Graft-versus-myeloma effects in reduced-intensity cord blood transplantation [3]

International Journal of Hematology

Volumn 86, Issue 5, 2007, Pages 463-465

  Miura, Yuji ^a,d   Azuma, Takayuki ^b   Kusumi, Eiji ^b   Matsumura, Tomoko ^c   Kami, Masahiro ^c   Komatsu, Tsunehiko ^a,b  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b Tsukuba Memorial Hospital   (Japan)

^c THE UNIVERSITY OF TOKYO   (Japan)

^d NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS MYELOMA EFFECT; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; REDUCED INTENSITY CONDITIONING;

AGED; BUSULFAN; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 38349038376     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02984008     Document Type: Letter

References (11)

1. Alyea E, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003;32:1145-1151.
2. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonnryeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447-3454.
3. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276-2285.
4. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275.
5. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815-1822.
6. Miyakoshi S, Yuji K, Kami M, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586-3592.
7. Lekakis L, Giralt S, Couriel D, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006;38:421-426.
8. Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol. 2007;86:49-54.
9. Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol. 2006;132:36-41.
10. Kusumi E, Kami M, Yuji K, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant. 2004;33:697-702.
11. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755-760.